Valneva(VALN) Newsfilter·2025-03-20 06:00Core Insights - Valneva SE reported consolidated financial results for the year ended December 31, 2024, highlighting double-digit sales growth and significant clinical and regulatory progress, setting the stage for future advancements in 2025 [1][3][5]. Financial Performance - Product sales increased by 13% to €163.3 million in 2024 from €144.6 million in 2023, while total revenues rose by 10% to €169.6 million from €153.7 million [6][35]. - The net loss for 2024 was €12.2 million, a significant improvement from a net loss of €101.4 million in 2023, largely due to the sale of a Priority Review Voucher [6][46][47]. - Operating cash burn was reduced by 67% to €67.2 million in 2024 compared to €202.7 million in 2023, with cash and cash equivalents at €168.3 million at year-end [5][49][51]. R&D and Regulatory Highlights - Valneva made substantial clinical and regulatory progress, including the completion of primary vaccinations in the Phase 3 study for its Lyme disease vaccine candidate, VLA15, and securing additional regulatory approvals for its chikungunya vaccine, IXCHIQ® [7][24][30]. - The company anticipates further data readouts and product approvals in 2025, with a focus on advancing its science-driven pipeline [5][6]. Product Portfolio - Valneva's commercial portfolio includes three vaccines: IXIARO®/JESPECT®, DUKORAL®, and IXCHIQ®, with IXIARO® sales increasing by 28% to €94.1 million in 2024 [10][11][36]. - DUKORAL® sales grew by 8% to €32.3 million, driven by increased demand in Canada [13][37]. - Initial sales of IXCHIQ® amounted to €3.7 million in 2024 following its launch in multiple markets [38]. Future Outlook - The company expects product sales to grow to €170-180 million and total revenues to reach €180-190 million in 2025, with R&D investments projected between €90-100 million [6][5]. - Valneva aims to maintain a strong cash position to support strategic investments while targeting a more than 50% reduction in operating cash burn in 2025 [5][6].